Results may vary. Actual vial appearance, contents, and dosage may vary and is based on your prescription. View full disclaimer in footer.*
Programs starting at $449/month.
Includes provider consult, prescription, and shipping.
Dual GIP/GLP-1 receptor agonist for advanced metabolic and weight management, delivered sublingually.
Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist — the first of its class. By activating two metabolic pathways simultaneously, it produces stronger appetite suppression and greater metabolic effects than GLP-1 alone. The SURMOUNT-1 trial demonstrated average weight loss of 22.5% body weight at the 15mg dose over 72 weeks — the largest weight loss ever recorded in a pharmaceutical trial at the time of publication. Sublingual compounded tirzepatide is a needle-free alternative for patients who prefer not to inject, prescribed and monitored by a licensed clinician with dose titration every 4 weeks.
*Price shown applies to 6-Month plan paid upfront or with buy now, pay later programs. Actual price will depend on product and plan prescribed.
**The FDA does not review or approve any compounded medications for safety or effectiveness.
Compounded medications are not FDA-approved drugs. They are prepared by licensed compounding pharmacies based on a clinician's prescription for an individual patient. Individual results vary. A medical evaluation is required to determine if this therapy is appropriate for you. Some uses discussed may be considered off-label.